Tocilizumab

Tocilizumab
Description

Product Description

Tocilizumab anti-IL-6R) is a humanized monoclonal antibody that binds to the interleukin-6 receptor

 

 

[accordions]
[accordion title= “Cell Research“]
Objective: To validate that IL-6 signaling is essential for TAM (tumor-associated macrophages)-enhanced CSC (cancer stem cells) function. Concentrations: 5 μg/ml. Incubation Time: 72 h. Method: For co-culture experiments, 12-well Transwell chambers were used with 2×105 HepG2 or Hep3B cells seeded in the lower chamber one day before co-culture and either 5×105 or 1×106 TAMs added in the upper chamber. Tocilizumab or human IgG antibody were added in indicated experiments to selected wells. After 24 to 72 hours, HCC cells and CD14+ TAM cells were collected separately for analysis. Cells:HepG2 cell lines, TAMs isolated from HCCs (hepatocellular carcinoma)
[/accordion]
[accordions]
[accordion title= “References and Literature“]
[/accordion]
[accordions]
[accordion title= “Chemical Properties“]
Molecular Weight 148 kDa
CAS No. 375823-41-9

[/accordion]